메뉴 건너뛰기




Volumn 46, Issue 7-8, 2012, Pages 1054-1064

Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors;Evaluación de las potenciales interacciones fármaco-fármaco entre derivados de ácido micofenólico e inhibidores de la bomba de protón

Author keywords

Drug interactions; Mycophenolate mofetil; Mycophenolic acid; Proton pump inhibitors

Indexed keywords

ATAZANAVIR; AZATHIOPRINE; CLOPIDOGREL; CYCLOSPORIN; KETOCONAZOLE; LANSOPRAZOLE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PANTOPRAZOLE; PREDNISOLONE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TACROLIMUS;

EID: 84864748051     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R071     Document Type: Article
Times cited : (22)

References (45)
  • 1
    • 10844292763 scopus 로고    scopus 로고
    • Immunosuppressive drugs for kidney transplantation
    • doi:10.1056/NEJMra033540
    • Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715-2729. doi:10.1056/NEJMra033540
    • (2004) N Engl J Med , vol.351 , pp. 2715-2729
    • Halloran, P.F.1
  • 3
    • 0008922584 scopus 로고    scopus 로고
    • Mycophenolate, Greenwood Village, CO: Thomson Micromedex. Expires December 31, 2013, accessed 2012 Mar 11
    • Mycophenolate. Drugdex system. Greenwood Village, CO: Thomson Micromedex. Expires December 31, 2013. http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/BABCA2/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/668B34/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/evidencexpert.IntermediateToDocumentLink?docId=0461&contentSetId=31&title=MYCOPHENOLIC+ACID&servicesTitle=MYCOPHENOLIC+ACID&topicId=null (accessed 2012 Mar 11).
    • Drugdex System
  • 4
    • 33846230492 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and pharmacodynamics ofmycophenolate in solid organ transplant recipients
    • Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics ofmycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 13-58
    • Staatz, C.E.1    Tett, S.E.2
  • 5
    • 80051785897 scopus 로고    scopus 로고
    • Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: Mycophenolate mofetil and enteric-coated mycophenolate sodium
    • doi:10.1097/TP.0b013e31822527ca
    • Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation 2011;92:426-432. doi:10.1097/TP.0b013e31822527ca
    • (2011) Transplantation , vol.92 , pp. 426-432
    • Ortega, F.1    Sanchez-Fructuoso, A.2    Cruzado, J.M.3
  • 6
    • 79959436407 scopus 로고    scopus 로고
    • Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
    • doi:10.1016/j.transproceed.2011.01.184
    • Reinke P, Budde K, Hugo C, et al. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplant Proc 2011;43:1641-1646. doi:10.1016/j.transproceed.2011.01.184
    • (2011) Transplant Proc , vol.43 , pp. 1641-1646
    • Reinke, P.1    Budde, K.2    Hugo, C.3
  • 7
    • 81855169543 scopus 로고    scopus 로고
    • Emergency hospitalizations for adverse drug events in older Americans
    • doi:10.1056/NEJMsa1103053
    • Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011;365:2002-2012. doi:10.1056/NEJMsa1103053
    • (2011) N Engl J Med , vol.365 , pp. 2002-2012
    • Budnitz, D.S.1    Lovegrove, M.C.2    Shehab, N.3    Richards, C.L.4
  • 8
    • 69549088254 scopus 로고    scopus 로고
    • Drug interactions in transplant patients: What everyone should know
    • doi:10.1097/MNH.0b013e32832edcb2
    • Manitpisitkul W, McCann E, Lee S, Weir MR. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009;18:404-411. doi:10.1097/MNH.0b013e32832edcb2
    • (2009) Curr Opin Nephrol Hypertens , vol.18 , pp. 404-411
    • Manitpisitkul, W.1    McCann, E.2    Lee, S.3    Weir, M.R.4
  • 9
    • 14744293831 scopus 로고    scopus 로고
    • Drug dosing in chronic kidney disease
    • S0025-7125. doi:10.1016/j.mcna.2004.11.007
    • Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Med Clin North Am 2005;89:649-687. S0025-7125. doi:10.1016/j.mcna.2004.11.007
    • (2005) Med Clin North Am , vol.89 , pp. 649-687
    • Gabardi, S.1    Abramson, S.2
  • 10
    • 69949163535 scopus 로고    scopus 로고
    • Immunotherapy in elderly transplant recipients: A guide to clinically significant drug interactions
    • doi:10.2165/11316480-000000000-00000
    • Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009;26:715-737. doi:10.2165/11316480-000000000-00000
    • (2009) Drugs Aging , vol.26 , pp. 715-737
    • Kuypers, D.R.1
  • 11
    • 0142244563 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium
    • doi:10.1345/aph.1D063
    • Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003;37:1685-1693. doi:10.1345/aph.1D063
    • (2003) Ann Pharmacother , vol.37 , pp. 1685-1693
    • Gabardi, S.1    Tran, J.L.2    Clarkson, M.R.3
  • 12
    • 0346996613 scopus 로고    scopus 로고
    • Mycophenolate mofetil in solid-organ transplantation
    • doi:10.1517/14656566.4.12.2325
    • Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003;4:2325-2345. doi:10.1517/14656566.4.12.2325
    • (2003) Expert Opin Pharmacother , vol.4 , pp. 2325-2345
    • Srinivas, T.R.1    Kaplan, B.2    Meier-Kriesche, H.U.3
  • 13
    • 0034981409 scopus 로고    scopus 로고
    • Prophylaxis and treatment of gastrointestinal complications following transplantation
    • Helderman JH. Prophylaxis and treatment of gastrointestinal complications following transplantation. Clin Transplant 2001;15(suppl 4):29-35.
    • (2001) Clin Transplant , vol.15 , Issue.SUPPL. 4 , pp. 29-35
    • Helderman, J.H.1
  • 14
    • 0034991912 scopus 로고    scopus 로고
    • Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities
    • Rubin RH. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant 2001;15(suppl 4):11-22.
    • (2001) Clin Transplant , vol.15 , Issue.SUPPL. 4 , pp. 11-22
    • Rubin, R.H.1
  • 15
    • 0034889041 scopus 로고    scopus 로고
    • Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management
    • Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001;24:645-663.
    • (2001) Drug Saf , vol.24 , pp. 645-663
    • Behrend, M.1
  • 17
    • 71249141502 scopus 로고    scopus 로고
    • Mycophenolate mofetil: An update
    • doi:10.1358/dot.2009.45.7.1384878
    • Villarroel MC, Hidalgo M, Jimeno A. Mycophenolate mofetil: an update. Drugs Today (Barc) 2009;45:521-532. doi:10.1358/dot.2009.45.7.1384878
    • (2009) Drugs Today (Barc) , vol.45 , pp. 521-532
    • Villarroel, M.C.1    Hidalgo, M.2    Jimeno, A.3
  • 18
    • 0042536429 scopus 로고    scopus 로고
    • Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
    • Knoll GA, MacDonald I, Khan A, van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003;14:2381-2386.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 2381-2386
    • Knoll, G.A.1    Macdonald, I.2    Khan, A.3    van Walraven, C.4
  • 19
    • 0027218826 scopus 로고
    • Immunosuppressive activity of mycophenolate mofetil
    • Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 1993;685:309-329.
    • (1993) Ann N Y Acad Sci , vol.685 , pp. 309-329
    • Eugui, E.M.1    Allison, A.C.2
  • 20
    • 0034045586 scopus 로고    scopus 로고
    • Mycophenolate mofetil and its mechanisms of action
    • Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118.
    • (2000) Immunopharmacology , vol.47 , pp. 85-118
    • Allison, A.C.1    Eugui, E.M.2
  • 21
    • 0029918886 scopus 로고    scopus 로고
    • Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF)
    • Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996;10:77-84.
    • (1996) Clin Transplant , vol.10 , pp. 77-84
    • Allison, A.C.1    Eugui, E.M.2
  • 22
    • 0027762592 scopus 로고
    • Human type I and II IMP dehydrogenases as drug targets
    • Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann N Y Acad Sci 1993;696:88-93.
    • (1993) Ann N Y Acad Sci , vol.696 , pp. 88-93
    • Natsumeda, Y.1    Carr, S.F.2
  • 23
    • 34548795914 scopus 로고    scopus 로고
    • Gastrointestinal complications in renal transplant recipients: MITOS study
    • doi:10.1016/j.transproceed.2007.07.015
    • Gil-Vernet S, Amado A, Ortega F, et al. Gastrointestinal complications in renal transplant recipients: MITOS study. Transplant Proc 2007;39:2190-193. doi:10.1016/j.transproceed.2007.07.015
    • (2007) Transplant Proc , vol.39 , pp. 2190-2193
    • Gil-Vernet, S.1    Amado, A.2    Ortega, F.3
  • 25
    • 12144273473 scopus 로고    scopus 로고
    • Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
    • doi:10.1007/s00147-004-0768-6
    • Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004;17:609-616. doi:10.1007/s00147-004-0768-6
    • (2004) Transpl Int , vol.17 , pp. 609-616
    • Hardinger, K.L.1    Brennan, D.C.2    Lowell, J.3    Schnitzler, M.A.4
  • 26
    • 40049085792 scopus 로고    scopus 로고
    • Increased risk of graft failure in kidney transplant recipients after a diagnosis of dyspepsia or gastroesophageal reflux disease
    • doi:10.1097/TP.0b013e318160d4c4
    • Neri L, Rocca Rey LA, Pinsky BW, et al. Increased risk of graft failure in kidney transplant recipients after a diagnosis of dyspepsia or gastroesophageal reflux disease. Transplantation 2008;85:344-352. doi:10.1097/TP.0b013e318160d4c4
    • (2008) Transplantation , vol.85 , pp. 344-352
    • Neri, L.1    Rocca, R.L.A.2    Pinsky, B.W.3
  • 27
    • 33747494883 scopus 로고    scopus 로고
    • Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure
    • doi:10.97/01.tp.0000225760.09969
    • Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006;82:102-107. doi:10.97/01.tp.0000225760.09969
    • (2006) Transplantation , vol.82 , pp. 102-107
    • Bunnapradist, S.1    Lentine, K.L.2    Burroughs, T.E.3
  • 29
    • 38549136645 scopus 로고    scopus 로고
    • Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation
    • doi:10.1097/FTD.0b013e31816337b7
    • Miura M, Satoh S, Inoue K, et al. Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. Ther Drug Monit 2008;30:46-51. doi:10.1097/FTD.0b013e31816337b7
    • (2008) Ther Drug Monit , vol.30 , pp. 46-51
    • Miura, M.1    Satoh, S.2    Inoue, K.3
  • 30
    • 65749114832 scopus 로고    scopus 로고
    • Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients
    • doi:10.16/j.healun.2009.03.006
    • Kofler S, Deutsch MA, Bigdeli AK, et al. Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. J Heart Lung Transplant 2009;28:605-611. doi:10.16/j.healun.2009.03.006
    • (2009) J Heart Lung Transplant , vol.28 , pp. 605-611
    • Kofler, S.1    Deutsch, M.A.2    Bigdeli, A.K.3
  • 31
    • 67649655600 scopus 로고    scopus 로고
    • Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective casecontrolled study
    • doi:10.1111/j.1600-6143.2009.02682.x
    • Kofler S, Shvets N, Bigdeli AK, et al. Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective casecontrolled study. Am J Transplant 2009;9:1650-1656. doi:10.1111/j.1600-6143.2009.02682.x
    • (2009) Am J Transplant , vol.9 , pp. 1650-1656
    • Kofler, S.1    Shvets, N.2    Bigdeli, A.K.3
  • 32
    • 78650470433 scopus 로고    scopus 로고
    • Proton pump inhibitor comedication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil
    • S0041-1345. doi:10.16/j.transproceed.2010.09.047
    • Doesch AO, Mueller S, Konstandin M, et al. Proton pump inhibitor comedication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. Transplant Proc 2010;42:4243-4246. S0041-1345. doi:10.16/j.transproceed.2010.09.047
    • (2010) Transplant Proc , vol.42 , pp. 4243-4246
    • Doesch, A.O.1    Mueller, S.2    Konstandin, M.3
  • 33
    • 78649355482 scopus 로고    scopus 로고
    • Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil
    • doi:10.1093/rheumatology/keq238
    • Schaier M, Scholl C, Scharpf D, et al. Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010;49:2061-2067. doi:10.1093/rheumatology/keq238
    • (2010) Rheumatology (Oxford) , vol.49 , pp. 2061-2067
    • Schaier, M.1    Scholl, C.2    Scharpf, D.3
  • 34
    • 70349479420 scopus 로고    scopus 로고
    • Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers
    • doi:10.1177/0091270009344988
    • Rupprecht K, Schmidt C, Raspe A, et al. Bioavailability of mycophenolate mofetil and enteric-coated mycophenolate sodium is differentially affected by pantoprazole in healthy volunteers. J Clin Pharmacol 2009;49:1196-1201. doi:10.1177/0091270009344988
    • (2009) J Clin Pharmacol , vol.49 , pp. 1196-1201
    • Rupprecht, K.1    Schmidt, C.2    Raspe, A.3
  • 35
    • 84864397182 scopus 로고    scopus 로고
    • Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers
    • 8 Sept 2011, doi:10.1177/0091270011412968
    • Kees MG, Steinke T, Moritz S, et al. Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers. J Clin Pharmacol Epub 8 Sept 2011. doi:10.1177/0091270011412968
    • J Clin Pharmacol Epub
    • Kees, M.G.1    Steinke, T.2    Moritz, S.3
  • 36
    • 79953777778 scopus 로고    scopus 로고
    • The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients
    • doi:10.1016/j.healun.2010.12.003
    • Kofler S, Wolf C, Shvets N, et al. The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. J Heart Lung Transplant 2011;30:565-571. doi:10.1016/j.healun.2010.12.003
    • (2011) J Heart Lung Transplant , vol.30 , pp. 565-571
    • Kofler, S.1    Wolf, C.2    Shvets, N.3
  • 37
    • 0037373072 scopus 로고    scopus 로고
    • Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients
    • Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. J Am Soc Nephrol 2003;14:721-727.
    • (2003) J Am Soc Nephrol , vol.14 , pp. 721-727
    • Neumann, I.1    Haidinger, M.2    Jager, H.3
  • 38
    • 77954764816 scopus 로고    scopus 로고
    • The CLEAR study: A 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation
    • doi:10.2215/CJN.09091209
    • Gourishankar S, Houde I, Keown PA, et al. The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. Clin J Am Soc Nephrol 2010;5:1282-1289. doi:10.2215/CJN.09091209
    • (2010) Clin J Am Soc Nephrol , vol.5 , pp. 1282-1289
    • Gourishankar, S.1    Houde, I.2    Keown, P.A.3
  • 39
    • 78751642276 scopus 로고    scopus 로고
    • The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: Evidence from the CLEAR study
    • doi:10.1097/FTD.0b013e318206a1b1
    • Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S. The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study. Ther Drug Monit 2011;33:120-123. doi:10.1097/FTD.0b013e318206a1b1
    • (2011) Ther Drug Monit , vol.33 , pp. 120-123
    • Kiberd, B.A.1    Wrobel, M.2    Dandavino, R.3    Keown, P.4    Gourishankar, S.5
  • 40
    • 13044305870 scopus 로고    scopus 로고
    • The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation
    • doi:10.1016/S0009-9236(98)90058-3
    • Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998;64:672-683. doi:10.1016/S0009-9236(98)90058-3
    • (1998) Clin Pharmacol Ther , vol.64 , pp. 672-683
    • Hale, M.D.1    Nicholls, A.J.2    Bullingham, R.E.3
  • 41
    • 77649116838 scopus 로고    scopus 로고
    • Mycophenolate mofetil versus enteric-coated mycophenolate sodium: A large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients
    • doi:10.1097/TP.0b013e3181ca860d
    • Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD. Mycophenolate mofetil versus enteric-coated mycophenolate sodium: a large, single-center comparison of dose adjustments and outcomes in kidney transplant recipients. Transplantation 2010;89:446-451. doi:10.1097/TP.0b013e3181ca860d
    • (2010) Transplantation , vol.89 , pp. 446-451
    • Sollinger, H.W.1    Sundberg, A.K.2    Leverson, G.3    Voss, B.J.4    Pirsch, J.D.5
  • 42
    • 28644442483 scopus 로고    scopus 로고
    • Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients
    • doi:10.1111/j.1399-0012.2005.00421.x
    • Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005;19:779-784. doi:10.1111/j.1399-0012.2005.00421.x
    • (2005) Clin Transplant , vol.19 , pp. 779-784
    • Tierce, J.C.1    Porterfield-Baxa, J.2    Petrilla, A.A.3    Kilburg, A.4    Ferguson, R.M.5
  • 43
    • 79958229595 scopus 로고    scopus 로고
    • Hudson, OH.: Lexi-Comp, Inc
    • Lexicomp online. Hudson, OH.: Lexi-Comp, Inc., 2011.
    • (2011) Lexicomp Online
  • 45
    • 84864741690 scopus 로고    scopus 로고
    • San Mateo, California, USA.: Epocrates, Inc
    • Epocrates Online. San Mateo, California, USA.: Epocrates, Inc., 2011.
    • (2011) Epocrates Online


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.